ClinicalTrials.gg

Churg-Strauss Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 61 studies for Churg-Strauss Syndrome across more than 10 countries. 17 are recruiting or about to start. 34 of them are mainly about Churg-Strauss Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
29
Recruiting
14
Status unknown
6
Active, not recruiting
5
Terminated
4
Not yet recruiting
2

Phase

Phase 3
11
Phase 2
11
Phase 4
4
Phase 1
3
Early Phase 1
1

Where

United States
26
United Kingdom
16
France
15
Canada
15
Italy
13
Germany
12

Who develops what

Add Churg-Strauss Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
mepolizumabRecent, limited
Evidence
  • NCT05979051 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Mepolizumab Injection” · registered Jul 2023
  • NCT04157348 · AstraZeneca · Phase 3 · live · comparator · “Mepolizumab” · registered Sep 2019
GlaxoSmithKline97% of its industry studiesUS: GlaxoSmithKline (FDA 2015)EU: GlaxoSmithKline (EMA 2015)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Churg-Strauss Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 3

Coming up

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger. 7 (50%) take children under 18. 1 (7%) are for women only and 0 (0%) for men only; 3 (21%) take healthy volunteers.

Recruiting studies that take each age, of 14
AgeWomenMen
107 (50%)7 (50%)
1813 (93%)12 (86%)
3012 (86%)11 (79%)
4012 (86%)11 (79%)
5012 (86%)11 (79%)
6511 (79%)11 (79%)
7511 (79%)11 (79%)
8511 (79%)11 (79%)

Across all 61 studies, recruiting or not: 13% stop at 75 or younger and 10% at 65; 20% take children; 3% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 61. Browse all 61 → or search them.